Hancock W D
Med Instrum. 1977 Mar-Apr;11(2):102-3.
The development of the prosthetic heart valve has led to the evolution of cardiac intensive care units, a better understanding of cardiac function and biocompatible materials, and new surgical procedures. Initial efforts with formaldehyde-fixed valves did not have long-term success. They led to the development of the stabilized glutaraldehyde process (SGP) valve and the flexible stent. The safety and efficacy of a heart valve bioprosthesis has been demonstrated through laboratory and animal experiments. Data on long-term clinical implants are needed to validate the results of these experiments.
人工心脏瓣膜的发展推动了心脏重症监护病房的演变、对心脏功能和生物相容性材料的更好理解以及新的外科手术。最初使用甲醛固定瓣膜的尝试并未取得长期成功。它们促成了稳定戊二醛处理（SGP）瓣膜和柔性支架的发展。心脏瓣膜生物假体的安全性和有效性已通过实验室和动物实验得到证明。需要长期临床植入的数据来验证这些实验的结果。
